Published in Lancet HIV on April 01, 2015
Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014. PLoS One (2017) 0.75
Maintenance of antiretroviral efficacy in children. Lancet HIV (2015) 0.75
A note on competing risks in survival data analysis. Br J Cancer (2004) 5.60
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis (2011) 3.04
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med (2012) 2.50
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr (2011) 2.39
Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ (2003) 2.34
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med (2009) 2.16
Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J (2009) 2.14
Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatr Infect Dis J (2011) 1.37
Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J (2009) 1.37
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children. AIDS Res Ther (2011) 1.22
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J (2008) 1.13
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis (2013) 1.12
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS (2008) 1.11
Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. AIDS (2011) 1.11
Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. AIDS Res Hum Retroviruses (2013) 1.03
Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa. PLoS One (2013) 1.03
Pediatric response to second-line antiretroviral therapy in South Africa. PLoS One (2012) 1.01
High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Res Ther (2012) 1.00
Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China. J Acquir Immune Defic Syndr (2011) 0.95
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis (2014) 0.91
Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy. J Acquir Immune Defic Syndr (2013) 0.91
Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. AIDS (2014) 0.87
Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand. J Acquir Immune Defic Syndr (2013) 0.85
Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat Genet (2006) 5.26
Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS (2008) 4.48
The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J (2009) 3.86
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
UK malaria treatment guidelines. J Infect (2007) 3.00
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS (2014) 2.67
Methods to recruit hard-to-reach groups: comparing two chain referral sampling methods of recruiting injecting drug users across nine studies in Russia and Estonia. J Urban Health (2006) 2.52
Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS (2002) 2.40
Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis (2007) 2.35
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J (2003) 1.90
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. Eur Heart J (2005) 1.84
Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr (2008) 1.75
Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect Dis (2003) 1.73
Effects of sex work on the prevalence of syphilis among injection drug users in 3 Russian cities. Am J Public Health (2006) 1.54
Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS (2009) 1.49
Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. J Hypertens (2007) 1.44
Multiple needle-stick injuries with risk of human immunodeficiency virus exposure in a primary school. Pediatr Infect Dis J (2006) 1.42
Tuberculin testing before BCG vaccination. BMJ (2003) 1.42
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis (2008) 1.40
Global epidemiology of paediatric tuberculosis. J Infect (2004) 1.39
Injecting equipment sharing among injecting drug users in Togliatti City, Russian Federation: maximizing the protective effects of syringe distribution. J Acquir Immune Defic Syndr (2004) 1.37
Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J (2006) 1.33
Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction (2004) 1.31
High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS (2006) 1.30
Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health (2003) 1.29
Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis (2010) 1.26
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine (2008) 1.25
Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS (2009) 1.23
Imported malaria in children: a review of clinical studies. Lancet Infect Dis (2007) 1.20
Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS (2005) 1.18
Childhood malaria in East London. Pediatr Infect Dis J (2003) 1.18
HIV and mitochondrial toxicity in children. J Antimicrob Chemother (2007) 1.18
Changes in laboratory features of 192 children with imported falciparum malaria treated with quinine. Pediatr Infect Dis J (2005) 1.17
Prevalence of personality disorder in alcohol and drug services and associated comorbidity. Addiction (2004) 1.15
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J (2008) 1.13
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther (2005) 1.12
Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS (2010) 1.09
Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat (2007) 1.05
National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and Links. Health Res Policy Syst (2011) 1.04
Pregnancy and HIV infection: A european consensus on management. AIDS (2002) 1.04
British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Med (2014) 1.01
Prognostic impact of demographic factors and clinical features on the mode of death in high-risk patients after myocardial infarction--a combined analysis from multicenter trials. Clin Cardiol (2005) 1.00
The epidemiology of tuberculosis in Europe. Arch Dis Child (2007) 0.99
Nevirapine use in HIV-1-infected children. AIDS (2003) 0.99
Over a decade of syringe exchange: results from 1997 UK survey. Addiction (2002) 0.98
Testing for HIV: concise guidance. Clin Med (2009) 0.98
Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. AIDS (2014) 0.96
Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009. J Acquir Immune Defic Syndr (2011) 0.94
Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS (2009) 0.94
HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS (2005) 0.94
Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial. BMC Infect Dis (2009) 0.93
Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J (2009) 0.93
Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J (2006) 0.91
Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J (2004) 0.90
Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS (2013) 0.90
Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy. AIDS Res Hum Retroviruses (2007) 0.89
When to start, what to start and other treatment controversies in pediatric HIV infection. Paediatr Drugs (2012) 0.89
Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial. J Infect Dis (2008) 0.89
Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. AIDS (2013) 0.88
Prospective, national clinical and epidemiologic study on imported childhood malaria in the United Kingdom and the Republic of Ireland. Pediatr Infect Dis J (2010) 0.88
Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis (2005) 0.88
Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis (2011) 0.87
Monitoring death and cancer in children born to HIV-infected women in England and Wales: use of HIV surveillance and national routine data. AIDS (2007) 0.87
Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. AIDS (2014) 0.87
Fatal histiocytic proliferative disorders in paediatric HIV infection with cytomegalovirus end-organ disease. Br J Haematol (2009) 0.86
Post-licensing safety of fosamprenavir in HIV-infected children in Europe. Pharmacoepidemiol Drug Saf (2014) 0.86
In utero exposure to antiretroviral therapy: feasibility of long-term follow-up. AIDS Care (2009) 0.85
Diagnostic Tests for Childhood Tuberculosis: Past Imperfect, Present Tense and Future Perfect? Pediatr Infect Dis J (2015) 0.85
Transmission of hepatitis C--are noninjecting cocaine users at risk? Subst Use Misuse (2002) 0.84
Lopinavir/ritonavir population pharmacokinetics in neonates and infants. Br J Clin Pharmacol (2011) 0.84
Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS (2009) 0.83
Nasopharyngeal carriage of Streptococcus pneumoniae: prevalence and risk factors in HIV-positive children in Tanzania. Int J Infect Dis (2012) 0.83
Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. PLoS One (2011) 0.82
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther (2011) 0.82
Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children. Curr Opin HIV AIDS (2012) 0.82
Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean? Antivir Ther (2007) 0.81
Clinical and microbiologic features guiding treatment recommendations for brain abscesses in children. Pediatr Infect Dis J (2013) 0.81
Optimising the dichotomy limit for left ventricular ejection fraction in selecting patients for defibrillator therapy after myocardial infarction. Heart (2007) 0.81
Potential demographic and baselines variables for risk stratification of high-risk post-myocardial infarction patients in the era of implantable cardioverter-defibrillator--a prognostic indicator. Int J Cardiol (2007) 0.81
Children with human immunodeficiency virus admitted to a paediatric intensive care unit in the United Kingdom over a 10-year period. Intensive Care Med (2003) 0.80